U.S. Markets closed

Oncology Treatments Retain Pricing Power: A Wall Street Transcript Interview with Boris Peaker, Ph.D., Executive Director and Senior Analyst with Oppenheimer & Co. Covering the Biotechnology Sector

67 WALL STREET, New York - April 28, 2014 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Biotechnology and Pharmaceutical Companies Valuation - Genetic and Cell Therapies

Companies include: Keryx Biopharmaceuticals Inc. (KERX), Celgene Corporation (CELG), InterMune Inc. (ITMN), NPS Pharmaceuticals, Inc. (NPSP) and many others.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector for investors:

TWST: There were some news reports talking about a "bursting of the biotech bubble." What was your take on that?

Dr. Peaker: I don't make that big of a deal of it. Realistically when you look at the overall performance of the industry over the last 18 to 24 months or so, it has been so strong that a small, relatively moderated correction is not unexpected. That's just the reality of the market. It doesn't take a lot to spook people after such a strong run.

I wouldn't necessarily call it the end of the world for biotech. It's a correction. It's reasonable. Fundamentals haven't really changed. There is still a lot of pricing power. There's still lot of revenue and earnings growth in most of the large caps in the industry. As an industry, it's far from being mature compared to some of the more established industrials.

TWST: Where are you pointing investors now? What are some of favorite stories at the moment?

Dr. Peaker: We have a number of companies that we like. Outside of the oncology space, we like Keryx (KERX). They are in the dialysis space, and we think that they have a very commercially attractive drug in development. In the large-cap oncology space, we like Celgene (CELG). We think based on its valuation it's a lot more attractive than some of the pharma companies out there.

We also like InterMune (ITMN). We think that it has a pretty attractive, unique drug. In the orphan space we like NPS Pharmaceuticals (NPSP). Again, very highly differentiated drugs.

TWST: Tell us a little bit about NPS.

Dr. Peaker: NPS has two drugs, one that has been launched and another that's likely going to get approved soon. Both are orphan drugs; they have no competition. The first one is very expensive, and we anticipate the second one will be, too. But there hasn't been much pushback from the reimbursement perspective...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.